Search results
Eric B. Lev General Partner. Wellesley. Eric, who joined Ampersand in 2013, has 18 years of middle market healthcare investment experience. Eric’s current and past board seats include ALPCO, Biologos, Biosynth, CutisPharma, Genoptix, iuvo Biosciences, LakePharma, Leinco Technologies, Nexelis, Nexcelom Biosciences, P95 and Resolian (formerly ...
Mr. Eric Lev serves as General Partner at Ampersand Capital Partners. He serves as Board Member at Interpace Biosciences. Mr. Lev has more than 17 years of experience in life science investing.
Experience: Aegon Asset Management · Education: USC Marshall School of Business · Location: Los Angeles, California, United States · 500+ connections on LinkedIn.
- 500+
- Multifamily Asset Management
- Aegon Asset Management
- Los Angeles
Jun 25, 2021 · Eric Lev, General Partner of Ampersand Capital Partners, added, "When Ampersand began its partnership with co-owners Peter Li and CTO & Founder Jean Qiu about three years ago, we saw promise in Nexcelom's technology and believed we could help the company leverage its unique solutions to expand its presence in therapeutics development and ...
Nov 17, 2021 · Eric Lev, General Partner at Ampersand and incoming Board member of Leinco, added, “Leinco is a tremendous fit with Ampersand’s investment strategy of supporting growth-oriented life science and healthcare organizations with established leadership positions in specialty segments of the market.
Eric Lev, General Partner at Ampersand noted, “P95 is another great fit in Ampersand’s strategy of supporting pharma services companies with leadership positions based on differentiated ...
Feb 26, 2013 · Ampersand Capital Partners, a healthcare-focused, middle-market private equity firm based in Wellesley, MA, has added three members to its management team. Eric Lev has joined the firm as a...
